Clinical Trials Logo

Alzheimer Disease clinical trials

View clinical trials related to Alzheimer Disease.

Filter by:

NCT ID: NCT00253227 Completed - Alzheimer Disease Clinical Trials

A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Start date: July 1997
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of galantamine (a drug for treating dementia) versus placebo in the treatment of patients with Alzheimer's disease using a flexible dose design.

NCT ID: NCT00253214 Completed - Alzheimer Disease Clinical Trials

Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation

Start date: March 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of a once daily controlled-release form of galantamine (a drug for treating dementia) versus placebo in the treatment of patients with Alzheimer's disease.

NCT ID: NCT00253201 Completed - Alzheimer Disease Clinical Trials

A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of two doses of galantamine (a drug for treating dementia) versus placebo in the treatment of patients with Alzheimer's disease.

NCT ID: NCT00253188 Completed - Alzheimer Disease Clinical Trials

A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Start date: February 1997
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of two doses of galantamine (a drug for treating dementia) versus placebo in the treatment of patients with Alzheimer's disease.

NCT ID: NCT00253123 Completed - Alzheimer Disease Clinical Trials

A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the safety and efficacy of risperidone (an antipsychotic medication) versus placebo in the treatment of behavioral disturbances associated with dementia.

NCT ID: NCT00249158 Completed - Alzheimer Disease Clinical Trials

A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia

Start date: March 1998
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare the effectiveness of an oral formulation of risperidone (an antipsychotic medication) to that of placebo for treating behavioral and psychological signs and symptoms in dementia (BPSSD), specifically aggression, delusions, and hallucinations, in patients with dementia.

NCT ID: NCT00249145 Completed - Alzheimer Disease Clinical Trials

A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia

Start date: April 1995
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare the safety and efficacy of risperidone (an antipsychotic medication) to that of placebo in the treatment of behavioral disturbances associated with dementia.

NCT ID: NCT00246896 Completed - Dementia Clinical Trials

Care Management for Patients With Alzheimer Disease and Their Family Caregivers

Start date: August 2001
Phase: N/A
Study type: Interventional

This is a clinical trial to test the effectiveness of current guideline for the care of older adults with Alzheimer's disease. The study focuses on the primary care setting using a nurse care manager to facilitate guideline-level care. We are hypothesizing that patients who receive guideline-level care will have fewer behavioral problems than those who receive the usual care provided in primary care settings

NCT ID: NCT00245206 Completed - Schizophrenia Clinical Trials

Side Effects of Newer Antipsychotics in Older Adults

Start date: August 2005
Phase: Phase 4
Study type: Interventional

This study will compare four atypical antipsychotic medications in terms of the risk of specific side effects each of them presents in middle-aged and elderly individuals.

NCT ID: NCT00244322 Completed - Alzheimer's Disease Clinical Trials

Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease

Start date: October 2005
Phase: Phase 2
Study type: Interventional

The purposes of this study are to determine: - The safety of LY450139 dihydrate and any side effects that might be associated with it. - How much LY450139 dihydrate should be given and how long it may be detected in blood. - To determine if LY450139 dihydrate may have an effect on a protein found in blood, called A beta. This protein is studied in subjects with Alzheimer's disease. - To collect and store samples from blood and spinal fluid for research related to Alzheimer's disease and similar (neurodegenerative) diseases or inflammation (irritation) that may provide information on how subjects respond to LY450139 or other medications. Length of study: Approximately 29 weeks. Number of office visits: 11 for most subjects: initial visit, every other week during 14 weeks of study drug treatment, and 2 follow-up visits. At no cost, approximately 45 eligible participants will receive: - Study medication - Study-related diagnostic and laboratory evaluations